Yong Qiang Zhu

GF Securities Co., Ltd. (Broker) also known as Gungfa Securities Co. Ltd., is the brokerage division of GF Securities Co. Ltd. (SZ: 000776; HK: 1776) in China. Established in 1991, the firm is based in Guangzhou and provides a range of brokerage services.

Manulife TEDA Fund Management Co. Ltd. (Manulife TEDA FM) is the fund management joint venture between Northern International Trust & Investment Co. Ltd. and Manulife Asset Management (Hong Kong) Ltd. Formerly known as ABN AMRO TEDA Fund Management Co. Ltd., the firm was established in 2002 as Tianjin TEDA Investment Holding Co., Ltd. Manulife TEDA FM is located in Beijing and manages a range of open-end funds, including equity, hybrid, bond and currency funds, for individual and institutional customers.

Penghua Fund Management Co., Ltd. (Penghua) is an independent Chinese investment management firm which was founded in 1998 to manage third party asset, principally through equities and fixed-income. In 2007 they set up a joint venture with Eurizon Financial Group (Intesa Sanpaolo), selling half of their capital to the Italian firm and Guosen Securities Co. Ltd. Headquartered Shenzhen, Penghua manages a range of mutual funds, including open- and closed-end funds, for institutional and retail investors.

Zhong Ou Asset Management Co., Ltd. (Zhong Ou AM) is a fund management firm headquartered in Shanghai, China. Formerly known as Lombarda China Fund Management Co., Ltd., the firm was founded in 2006 as a joint venture between UBI, Guodu Securities Co., Ltd., China Private Ventures (Beijing) Ltd. and WinnerKey Investment Co., Ltd. Zhong Ou AM manages mutual funds and provides financial advisory services to both Chinese and global institutional, as well as retail investors.

Ping An Securities Co. Ltd. is the securities brokerage subsidiary of Ping An Trust Co., Ltd., which is owned by Ping An Insurance (Group) Co. of China Ltd. (SHA: 601318; HKG: 2318). Headquartered in Shenzhen, the firm was founded in 1991 and provides institutional brokerage services based on the needs of professional investors such as private equity, public equity, trust, asset management, general corporate institutions, and high-net-worth clients.

Part of Shenzhen Capital Group Co., Ltd., Hotland Innovation Asset Management Co. Ltd. is a company that provides investment advice. The company is based in Shenzhen, China. The Chinese company was founded in 2014. The CEO is Hong Tao Ji.

HSBC Jintrust Fund Management Co. Ltd. (HSBC Jintrust) is a mutual fund management firm headquartered in Shanghai, China. The firm was founded in 2005 as a joint venture between HSBC Global Asset Management (formerly HSBC Investments UK Ltd.) and Shanxi Trust and Investment Ltd. HSBC Jintrust provides investment advice services and account management.

China Southern Asset Management Co., Ltd. (CSAM) is an independent Chinese fund management firm which was founded in 1998. Headquartered in Shenzhen, the firm launched China's first listed open-ended fund in 2004 and manages a range of close-ended and open-ended investment funds for institutional clients and private individuals. They are one of the investment managers selected by the Chinese government to manage an institutional mandate for the National Social Security Fund. In 2007, CSAM acquired QDII status (Qualified Domestic Institutional Investors) allowing them to invest in the overseas capital markets under the foreign exchange control system in China. They announced the launching, in cooperation with US-based Mellon Financial Corporation, of their first QDII investment fund in 2007.

JX Asset Management Co.,Ltd provides investment advice. The private company is based in Shenzhen, China. and has subsidiaries in China. The Chinese company was founded in 2015. The CEO is Ke Sheng Yin.

China CITIC Bank provides international commercial banking services. It is led by the People's Bank of China and CITIC. The company was founded in 1987 and is located in Beijing, China.

ENSEM Therapeutics, Inc. is a drug discovery and development company that specializes in developing small molecule precision medicines for oncology. The company is based in Waltham, MA. The company leverages its unique Kinetic Ensemble® platform to develop innovative drugs. The company has a potential oral CDK2 inhibitor, PI3K?, and a number of early-stage discovery programs at various stages of maturity launched with their Kinetic Ensemble® platform. ENSEM Therapeutics was founded by Shenfang Jin, Qi Zhang, Cheng Luo, and Shenfang Jin has been the CEO since incorporation.